Mahdi Taha, DO
Medical Oncology · Boca Raton, FLNPI 1346488061
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,202,663 of the $1,682,610 with a category attached, or 71.5%. 60 manufacturers reported payments, led by Johnson & Johnson at 33.4% of the total. 2025 is the largest year on record at $452,340, 3.1 times the $144,906 reported in 2019. Among medical oncology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,873 payments — averaging $585.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$562K
- Eisai Inc.$410K
- AstraZeneca$164K
- Seagen Inc.$67K
- Merck$65K
- Regeneron Healthcare Solutions, Inc.$65K
- plus $349K from 54 others
Across 13 payments — averaging $31,576 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- E.r. Squibb & Sons, L.L.C.$292K
- Pfizer$102K
- AstraZeneca$17K
What the payments were for
- Consulting fees$167,28210%
- Speaking & faculty fees$1,202,66371%
- Travel & lodging$249,61015%
- Food & beverage$61,8214%
- Education$1,2350%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,682,610 in reported general payments places this provider in the 95th percentile of 507 medical oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 127 | $1,531,890 |
| LenvimaLenvatinib Mesylate | 23 | $424,153 |
| XtandiEnzalutamide | 39 | $406,643 |
| RevlimidLenalidomide | 17 | $304,775 |
| BrukinsaZanubrutinib | 25 | $288,632 |
| TalzennaTalazoparib Tosylate | 24 | $240,552 |
| KisqaliRibociclib Succinate | 11 | $166,384 |
| OrgovyxRelugolix | 36 | $92,033 |
| Sunitinib Malate | 16 | $65,927 |
| Abiraterone Acetate | 45 | $49,683 |
| XareltoRivaroxaban | 11 | $9,450 |
| VeozahFezolinetant | 16 | $8,687 |
| JanuviaSitagliptin Phosphate | 14 | $8,649 |
| EliquisApixaban | 12 | $6,993 |
| Ondansetron OdtOndansetron | 73 | $1,913 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada, Xarelto | $561,812 | $1,541,340138 claims |
| Eisai Inc.Lenvima | $410,078 | $424,15323 claims |
| Astellas Pharma US IncXtandi, Veozah | $56,991 | $415,33055 claims |
| Bristol Myers SquibbRevlimid | $427 | $304,77517 claims |
| Beigene USA, Inc.Brukinsa | $185 | $288,63225 claims |
| PfizerTalzenna, Eliquis | $55,529 | $247,54536 claims |
| NovartisKisqali | $9,109 | $166,38411 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $1,010 | $49,68345 claims |
| MerckJanuvia | $65,132 | $8,64914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 507 medical oncology providers in Florida.
Other medical oncology in Boca Raton
- Mohammad JahanzebBoca Raton$1.3M
- Neil LoveMiami$5.6M
- Raji ShameemOrlando$1.3M
- Michel VelezOrlando$927K
- Yuanbin ChenOrlando$810K
- Reshma MahtaniPlantation$608K
- Rebecca MorooseOrlando$543K
- Yasser KhaledOrlando$444K
- Judah FriedmanPalm Beach Gardens$416K
- Guru SonpavdeOrlando$400K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.